WW International, Inc. or WeightWatchers (NASDAQ:WW) stock surged Monday after it reported second-quarter 2025 combined revenues of $189 million, down 6% from the prior year. Growth in Clinical subscriptions offset declines in the Behavioral segment.
Clinical subscription revenues rose 55% to $30.59 million, driven primarily by compounded semaglutide prescriptions, while Behavioral subscription revenues fell 12.7% to $157.3 million. Other revenues decreased 38% to $1.3 million.
